SERVICES
How we tackle projects
myNEO Therapeutics offers myNEO intelligence, your go-to partner for immunogenomic, end-to-end services across the different stages of your IO development pipeline. Our neoantigen discovery expert team closely collaborates with our clients and partners wherein open communication and flexibility is key. We go the extra mile for your project and strive to achieve the highest quality within the set milestones, timeline, and budget.
Definition of work packages
Assembly of expert team
Distribution of workload
Tracking of milestones
Regular communication
Detailed reporting
Target discovery
Early discovery of cancer neo(antigen) targets
Screening omics databases and patient biopsies
Matching tumor neoantigen targets with population of interest for optimal coverage
Selection of an optimal set of immunogenic epitopes
Differential expression analysis and genome-wide association studies
Target selection
SNVs & Indels, gene fusions, RTE insertions, neoisoforms,…
Other cancer events: TMB, MET exon14 skipping,…
Target prioritization based on proprietary algorithms
neoMS: MHC-presentation
neoIM: immunogenicity scoring
Functional relevance, clonality, immune-escape likelihood
Coordination of biopt sequencing
Set up safe cloud infrastructures
Pre-clinical
Construct design
Incorporation of epitope subsets into larger constructs
Shuffling epitopes and linkers to optimize the efficacy and safety
Design and coordination of pre-clinical validation experiments
Target confirmation in patient biopsies
In-vitro immunogenicity assays
MS ligandomics
In-vitro tumor killing assays
Organoid assays
Scientific advice and support of the pre-clinical roadmap
KOL support from lead candidate(s) selection to IND studies
Support in the selection of manufacturing site for R&D product and GMP product
Mechanism of action (MoA) and pathway analysis
Using QIAGEN Ingenuity Pathway Analysis
Starting from RNAseq datasets
Clinical
Deep investigation of patient data
Omics, TCRseq, ELISpot, ICS, MSD 30-plex, IHC, immunophenotyping, Nanostring, …
ctDNA patient monitoring and follow-up
Tumor-specific mutational profiling
Comparison vs digital genomic twin with similar immuno-genomic profile
Biomarker identification based on clinical trial results
Pre-treatment biomarkers for patient stratification
Early biomarkers correlating with clinical response
Patient-centric translational data analysis
Therapy response prediction
TMB, MSI , immunogenic neoantigen load
Tumor heterogeneity, TME classification
AI-driven multi-parametric analysis
Experimental design
Set-up of patient data visualization platform
How do we offer services?
One-time Only Service Agreement
Project scope defined by the client
Project proposal with well-defined timelines, costs & deliverables
Results delivered via a final report (report format chosen by the client: simple vs interactive report)
Final meeting wherein the project results are discussed
Long-term Master Service Agreement
(MSA) + monthly work orders
Fixed daily fee based on FTE effort & tech access
Set-up monthly work orders with predictable timelines, costs, deliverables
Fine-tuning/adaptations during the project are possible
Meetings with the client on weekly basis
Innovating immunotherapies,
transforming tomorrow
Subscribe to our newsletter
Get the latest news & updates about myNEO Therapeutics
Home
About us
Products
Technology
Partners
Services
Contact
Quick links
Publications
Latest news
Privacy statement
Terms of use
Careers
Cookie statement
We use cookies to enhance your browsing experience and provide analytics. By continuing to use this website, you agree to our use of cookies. For more information, please read our privacy statement.